Heart disease

Cardiovascular disease is the primary source of death in the world, killing more than 20 million people every year through conditions, such as heart attack, stroke and heart failure. We  are dedicated to advancing cardiac health by providing transformative tissue engineering solutions for research, drug development and regenerative medicine.

With our Nexocyte tissue engineering platform, we are able to engineer functional cardiac tissues for use as in vitro research models or for regenerative research applications with cell level precision. Using our high-resolution 3D bioprinting technology Biopixlar, we can create everything from complex cardiac tissue sections that accurately mimic human histology to precisely engineered cardiac organoids.

Fluicell’s tissue engineering technology allows us to target heart disease and cardiac safety in multiple ways. We are currently developing cardiac tissue models with applications across cardiac safety screening as well as cardiac disease modeling. Most currently used cell-based cardiac models are either monocultures or simple mixtures, and do not account for cell type diversity, ECM composition, cell-cell interactions, and microenvironment geometry. Our advanced cardiac models are developed to target some of the main challenges to achieve fully predictive in vitro models:

Fluicell is engaged in the development of human tissue-based models for cardiac safety screening. Cardiac toxicity is a common cause of drug candidates failing in the clinical phase, and new advanced models that can provide predictive answers earlier in the development process can lead to major cost savings. Since 2021, Fluicell has conducted product development in the field in collaboration with a top-10 pharmaceutical company and is currently actively collaborating with the goal of investigating the possibility of integrating Fluicell's bioprinted tissues into the pharmaceutical company's workflows.